McDermott and Bull executive Search
 

Other News

DiNAQOR Appoints Medical Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and Production

Financial by 0 comments

ZURICH-SCHLIEREN, Switzerland and LAGUNA HILLS, Calif., Sept. 23, 2021 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced it has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to serve as Executive Vice President, Medical Devices. As the company grows its U.S. footprint, Mr. Dehdashtian […]

Continue Reading →

Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease

Financial by 0 comments

Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease Copenhagen, Denmark, 23 September 2021 – Draupnir Bio (“Draupnir”), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces the establishment of its scientific advisory board (SAB) comprising global leaders in carbohydrate chemistry, the regulation […]

Continue Reading →

Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease

Coronary/Structural Heart by 0 comments

Treatment of Non-Human Primates with Clinical Candidate, VERVE-101, Led to Durable Reductions of PCSK9 Protein and Low-density Lipoprotein Cholesterol Comprehensive Off-Target Editing Analysis Using Industry Leading Methods, ONE-seq and Digenome-seq Showed No Off-Target Editing Across 244 Potential Sites in Human Liver Cells Data Support Continued Advancement of VERVE-101 Toward IND Submission […]

Continue Reading →

Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

Financial by 0 comments

Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today […]

Continue Reading →

NeuroVasc Announces First Patient Enrolled in ENVI™-SR Mechanical Thrombectomy System Clinical Trial in China

Neuro by 0 comments

Pivotal trial will assess use of the device for blood clot removal in strokes IRVINE, Calif.–(BUSINESS WIRE)–NeuroVasc Technologies, Inc. today announced that the first patient has been treated in a Chinese Pivotal Randomized Controlled Trial to evaluate the safety and efficacy of the ENVI™-SR Mechanical Thrombectomy System (ENVI™-SR), a stent-retriever for […]

Continue Reading →

MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study

Peripheral/Endo by 0 comments

GENEVA, Switzerland, Sept. 22, 2021 /PRNewswire/ — MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clinical Trial Notification (CTN) by Japan’s Pharmaceutical and Medical Device Agency […]

Continue Reading →

Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management

Coronary/Structural Heart by 0 comments

Guidelines support the Carillon Mitral Contour System® for the treatment of heart failure patients with secondary functional mitral regurgitation KIRKLAND, Wash., Sept. 22, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their […]

Continue Reading →

MCRA Expands Neurology Division into Neurointerventional Market

Neuro by 0 comments

– Robert Herrmann, Ph.D, Former U.S. Food & Drug Administration (FDA) Team Lead and Lead Reviewer for Neurointerventional and Neurosurgical Devices joins MCRA as Director, Neurointerventional Regulatory Affairs. WASHINGTON, Sept. 22, 2021 /PRNewswire/ — MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization (CRO) integrating U.S. and International […]

Continue Reading →
1 2 3 … 634